# US 10,502,736 B2 · Treating multiple sclerosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,502,736 B2
- Document ID: US10502736B2
- Status: Granted
- Kind: B2
- Application number: 15/629,697
- Filed: 2017-06-21
- Published: 2018-02-08
- Granted: 2019-12-10
- Earliest claimed: 2011-06-13
- Assignees: Tla Targeted Immunotherapies AB
- Applicants: Tla Targeted Immunotherapies AB
- Inventors: Ola Winqvist; Graham Cotton
- Web page: https://patentgrep.com/patent/US10502736B2

## CPC

- A61M 1/3679: {by absorption (A61M1/3675 takes precedence)}
- A61M 1/3618: {Magnetic separation}
- G01N 33/566: using specific carrier or receptor proteins as ligand binding reagents {where possible specific carrier or receptor proteins are classified with their target compounds}
- G01N 33/56972: {White blood cells}
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- G01N 2333/7158: for chemokines
- G01N 2800/065: Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor CCR2, CCR6, CCR3, CCR5, CCR1, CXCR3 and/or CCR9 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally CCR2, CCR6, CCR3, CCR5, CCR1, CXCR3 and/or CCR9 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.

## Claims

### Claim 1

A method for treating multiple sclerosis in a subject in need thereof comprising applying peripheral blood from the subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor CCR2 immobilized directly or indirectly on the support, whereby one or more cells expressing the chemokine receptor CCR2 are removed from the peripheral blood of the subject, wherein blood applied to the apheresis column is circulated back into the subject's systemic circulation, and whereby the multiple sclerosis is treated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the multiple sclerosis is selected from active and stable relapsing-remitting multiple sclerosis, primary progressive relapsing multiple sclerosis, secondary progressive relapsing multiple sclerosis, and progressive relapsing multiple sclerosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the binding reagent is an agonist or an antagonist of CCR2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the binding reagent is an antibody or a chemokine.

### Claim 5 (depends on 4)

The method of claim 4, wherein the chemokine is selected from MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5.

### Claim 6 (depends on 5)

The method of claim 5, wherein the chemokine is MCP-1 or MCP-5.

### Claim 7 (depends on 1)

The method of claim 1, wherein the one or more cells are selected from monocytes, lymphocytes, neutrophils, macrophages, eosinophils, and basophils.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has increased levels of expression of CCR2 as compared to a subject that does not have multiple sclerosis.

### Claim 9 (depends on 1)

The method of claim 1, wherein 20-50% of the subject's blood is applied to the column in a single treatment.